Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUISE CONTROL
2010-024552-28Phase 4Completed
- Sponsor
- Oxford University Hospitals
- Start
- Aug 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of warfarin, heparin and low molecular weight heparin calcium in thromboembolism, Atrial fibrillation (AFib), atrial flutter (AFL) and 2 more (2 arms), sponsored by Oxford University Hospitals. Primary endpoint: Clinically significant haematoma. Started Aug 2012; status: completed.
02
Drugs
warfarinheparinlow molecular weight heparin calcium
03
Conditions
thromboembolismAtrial fibrillation (AFib)atrial flutter (AFL)venous thromboembolism (VTE)heart valve prosthesis
Beyond the preview
Go deeper on 2010-024552-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024552-28.